Christian Olsen

As multispecific antibodies and antibody drug conjugates outgrow legacy LIMS and ELN platforms, drug developers face a problem more costly than fragmented workflows: scientific reasoning evaporates at every handoff, forcing the next team to start from scratch.

The shift from looking at lots of possibilities to focusing on specific ones in a drug discovery pipeline is why traditional pipelines don’t work well.